Literature DB >> 15716077

Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.

Olgica Djurković-Djaković1, Aleksandra Nikolić, Branko Bobić, Ivana Klun, Anastasija Aleksić.   

Abstract

The mouse-virulent RH strain of Toxoplasma gondii is generally considered to have lost its cyst-forming capacity, and conversion of RH tachyzoites into cysts in non-immune mice has previously been shown exclusively following early treatment with sulfadiazine (SDZ). We here describe the development of tissue cysts in mice infected with RH strain parasites and treated with atovaquone (ATO) combined with pyrrolidine dithiocarbamate (PDTC). Groups of Swiss-Webster mice infected intraperitoneally (i.p.) with 10(2) RH tachyzoites were treated with 5, 25 and 100 mg of ATO/kg per day alone or combined with PDTC at 250 mg/kg per day from day 1 postinfection (p.i.) for 14 days. A total of 19 mice survived the 6-week observation period. Of these, brain cysts were recovered in nine (47%), with burdens ranging from 50 to 3120 (mean +/- S.D. = 622 +/- 963). All cyst-harboring mice had high specific IgG antibody levels (1:10,240-1:40,960, corresponding to 500-2000 IU/ml), as did one mouse in which cysts were not demonstrated, which was therefore included in the group of mice with residual infection. Bioassay performed to test the infectivity of these cysts produced acute lethal toxoplasmosis following i.p. inoculation in all instances (100%), and importantly, following peroral inoculation in four (29%). The recovered tachyzoites were highly infectious. In addition, significantly elevated interferon gamma (IFN-gamma) in the treated mice which developed residual infection compared with any group of infection-free (treated or subinoculated) mice, indicates immunological control of the parasite in the latent form. In conclusion, early treatment of mice infected with T. gondii RH tachyzoites with ATO and PDTC induces conversion into tissue cysts, thus providing a new model for studying the mechanism(s) of T. gondii stage conversion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15716077     DOI: 10.1016/j.micinf.2004.09.016

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  14 in total

1.  Mycophenolic acid induces differentiation of Toxoplasma gondii RH strain tachyzoites into bradyzoites and formation of cyst-like structure in vitro.

Authors:  Kitzia N Castro-Elizalde; Pedro Hernández-Contreras; Carlos J Ramírez-Flores; Sirenia González-Pozos; Carmen T Gómez de León; Mónica Mondragón-Castelán; Ricardo Mondragón-Flores
Journal:  Parasitol Res       Date:  2018-01-08       Impact factor: 2.289

2.  Experimental infection with Toxoplasma gondii in broiler chickens (Gallus domesticus): seroconversion, tissue cyst distribution, and prophylaxis.

Authors:  Maria E Nedişan; Adriana Györke; Cristina L Ştefănuţ; Zsuzsa Kalmár; Zsuzsa Friss; Radu Blaga; Amandine Blaizot; Andra Toma-Naic; Viorica Mircean; Gereon Schares; Olgica Djurković-Djaković; Ivana Klun; Isabelle Villena; Vasile Cozma
Journal:  Parasitol Res       Date:  2021-01-08       Impact factor: 2.289

3.  Detection of Toxoplasma gondii in naturally infected domestic pigs in Northern Serbia.

Authors:  Ljiljana Kuruca; Ivana Klun; Aleksandra Uzelac; Aleksandra Nikolić; Branko Bobić; Stanislav Simin; Vesna Lalošević; Dušan Lalošević; Olgica Djurković-Djaković
Journal:  Parasitol Res       Date:  2017-09-27       Impact factor: 2.289

4.  Reduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound.

Authors:  J A Portes; T G Souza; T A T dos Santos; L L R da Silva; T P Ribeiro; M D Pereira; A Horn; C Fernandes; R A DaMatta; W de Souza; S H Seabra
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites.

Authors:  J A Portes; W De Souza
Journal:  Parasitol Res       Date:  2019-11-14       Impact factor: 2.289

Review 6.  Mechanisms of Toxoplasma gondii persistence and latency.

Authors:  William J Sullivan; Victoria Jeffers
Journal:  FEMS Microbiol Rev       Date:  2011-10-04       Impact factor: 16.408

7.  A new iron(III) complex-containing sulfadiazine inhibits the proliferation and induces cystogenesis of Toxoplasma gondii.

Authors:  Juliana de A Portes; Nathália F B Azeredo; Pedro G T Siqueira; Tatiana Guinancio de Souza; Christiane Fernandes; Adolfo Horn; Dalber R S Candela; Wanderley de Souza; Renato A DaMatta; Sérgio H Seabra
Journal:  Parasitol Res       Date:  2018-06-22       Impact factor: 2.289

8.  Toxoplasma gondii infection in slaughter pigs in Serbia: seroprevalence and demonstration of parasites in blood.

Authors:  Ivana Klun; Marija Vujanić; Hélène Yera; Aleksandra Nikolić; Vladimir Ivović; Branko Bobić; Siniša Bradonjić; Jean Dupouy-Camet; Olgica Djurković-Djaković
Journal:  Vet Res       Date:  2011-02-01       Impact factor: 3.683

9.  Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and development.

Authors:  Jay R Radke; Robert G Donald; Amy Eibs; Maria E Jerome; Michael S Behnke; Paul Liberator; Michael W White
Journal:  PLoS Pathog       Date:  2006-10       Impact factor: 6.823

10.  The transcription of bradyzoite genes in Toxoplasma gondii is controlled by autonomous promoter elements.

Authors:  Michael S Behnke; Josh B Radke; Aaron T Smith; William J Sullivan; Michael W White
Journal:  Mol Microbiol       Date:  2008-04-21       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.